June 12, 2012
When Practitioners Harm More Than Heal
“Missing The Target: When Practitioners Harm More Than Heal” is the title of a two-day conference in Washington this week (June 14-15) hosted by PharmedOut.org at Georgetown. This is their third annual conference – this one focusing on how patient harms may result from industry promotions.
The full agenda and abstracts are now available online.
Some of the speakers:
- Rita Redberg, M.D., M.Sc., Archives of Internal Medicine Editor-in-Chief; professor of medicine, University of California, San Francisco
- Carl Elliott, M.D. Ph.D., author, White Coat, Black Hat; professor, University of Minnesota’s Center for Bioethics
- Kay Dickersin, Ph.D., director, Center for Clinical Trials, Johns Hopkins Center for Global Health
- Julie Taitsman, M.D., J.D., chief medical officer, Office of the Inspector General, U.S. Department of Health and Human Services
- Sharon Treat, J.D., executive director, National Legislative Association on Prescription Drug Prices
- Thomas M. Burton, Pulitzer Prize winning-journalist, The Wall Street Journal
- Shannon Brownlee, M.S., author, Overtreated; acting director, New America Foundation Health Policy Program
- Susan Wood, PhD, George Washington University
- Sean Flynn, JD, American University
- Joel Lexchin, MD, York University
- Barbara Mintzes, Therapeutics Initiative
Some of the topics:
- Marketing of antipsychotic medications and other drugs
- Potential health risks of CT scans and other medical devices
- Legislative and regulatory updates and solutions
- The role of industry, media, and payers in informing and protecting patients
- The Underuse of Classic Drugs
- Are Medical Devices and Drugs Adequately Regulated?
- Protecting Patients in Industry-Funded Trials
- Pharmaceutical Marketing and Adverse Health Outcomes
You might also like
-
Shortly before Christmas Inside Health Policy, a trade pub that covers the drug industry and…
-
Last week a guideline recommendation from the US Preventive Services Task Force (USPSTF), published in the Journal…
-
What are those clever drug companies up to? Plenty, I learned, recently browsing the website…
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like
Shortly before Christmas Inside Health Policy, a trade pub that covers the drug industry and…
Last week a guideline recommendation from the US Preventive Services Task Force (USPSTF), published in the Journal…
What are those clever drug companies up to? Plenty, I learned, recently browsing the website…